Test Type: CHRONIC

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1** Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

Lab: BAT

F1_M3

Species/Strain: MICE/B6C3F1

Route: SKIN APPLICATION

C Number: C99032

Lock Date: 03/04/2008

Cage Range: ALL

ALL **Date Range:**

ALL **Reasons For Removal:**

Removal Date Range: ALL

Include ALL **Treatment Groups:**

Study Gender: Both

TDMSE Version: 2.2.0

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Disposition Summary					
Animals Initially In Study	50	50	50	50	
Early Deaths					
Accidently Killed				1	
Moribund Sacrifice	8	10	10	12	
Natural Death	5	4	6	6	
Survivors					
Terminal Sacrifice	37	36	34	31	
Animals Examined Microscopically	50	50	50	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Inflammation	, ,	, ,		1 [3.0]	
Epithelium, Cyst				1 [4.0]	
Gallbladder	(49)	(49)	(50)	(46)	
Cyst	1 [2.0]	,	,	,	
Infiltration Cellular, Mononuclear Cell	4 [1.0]	8 [1.0]	4 [1.0]	3 [1.0]	
Epithelium, Hyperplasia	1 [2.0]		1 [2.0]		
Intestine Large, Cecum	(50)	(50)	(50)	(50)	
Hyperplasia, Lymphoid			1 [4.0]		
Inflammation			1 [3.0]		
Epithelium, Hyperplasia				1 [2.0]	
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Intestine Large, Rectum	(50)	(50)	(50)	(50)	
Inflammation			1 [1.0]		
Epithelium, Hyperplasia			2 [2.0]		
Muscularis, Hypertrophy			1 [2.0]		
Intestine Small, Duodenum	(50)	(50)	(50)	(50)	
Inflammation		1 [1.0]			
Epithelium, Hyperplasia		1 [3.0]			
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Inflammation		2 [2.0]	5 [2.2]		
Epithelium, Hyperplasia		2 [2.0]	2 [2.0]		
Intestine Small, Jejunum	(50)	(50)	(50)	(50)	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol CAS Number: 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

Cyst James of the period of the	B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Hyperplasia, Lymphoid					4 [0.0]	
Inflammation 1 [1.0] 2 [2.5] 3 [2.7] Inflammation, Granulomatous 1 [1.0] 1 [1.0] Epithelium, Hyperplasia 1 [2.0] 1 [1.0] Liver (50) (50) (50) Anglectasis 1 [2.0] 1 [2.0] Atypia Cellular 1 [2.0] 1 [2.0] Basephilic Focus 5 7 7 7 Clear Cell Focus 29 31 29 23 Cytoplasmic Alteration 1 [1.0] 1 [2.0] 1 [2.0] Degeneration, Fatty 1 [3.0] 2 2 Eosinophilic Focus 31 32 31 26 Fibrosis 1 [2.0] 2 1 Hematopoietic Cell Proliferation 2 1 [4.0] 1 [4.1] Hepatodiaphragmatic Nodule 2 1 [4.0] 1 [4.0] Inflaret 1 [2.0] 2 [1.0] 2 [1.0] Mixed Cell Focus 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0]<	=	0.14.41	5 [4 0]	5 [4 0]	1 [3.0]	
Inflammation, Granulomatous						
Epithelium, Hyperplasia			2 [2.5]	3 [2.7]		
Liver (50) (50) (50) (50) Angictasis 1[2.0] Atypia Cellular 1[2.0] Basophilic Focus 5 7 7 7 Clear Cell Focus 29 31 29 23 Cytoplasmic Alteration 1[1.0] 1[2.0] 1 Degeneration, Fatty 1[3.0] 2 31 26 Eosinophilic Focus 31 32 31 26 Fibrosis 1[2.0] 4[1.3] 4[1.5] 14[1.4] Hematopoietic Cell Proliferation 4 [1.3] 4 [1.5] 14[1.4] Hepatodiaphragmatic Nodule 2 1 [4.0] 14[1.4] Hepatodiaphragmatic Nodule 2 2 [1.0] 29[1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] 2 [1.0] 4 [3.0] Mixed Cell Focus 5 5 6 8 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 3 [3.3] 2 [1.5]		1 [1.0]	4 70 01		4.54.03	
Angiectasis Atypia Cellular Basophilic Focus 5 7 7 7 7 Clear Cell Focus 29 31 29 23 Cytoplasmic Alteration Degeneration, Fatty 11(2.0) Eosinophilic Focus 31 32 31 26 Fibrosis 11(2.0) Hematopoietic Cell Proliferation Hematopoietic C		(50)		(=0)		
Atypia Cellular Basophilic Focus 5 7 7 7 7 Clear Cell Focus 29 31 29 23 Cytoplasmic Alteration 1 [1.0] 1 [2.0] Degeneration, Fatty 1 [3.0] Eosinophilic Focus 31 32 31 26 Fibrosis 1 [2.0] Hematopoietic Cell Proliferation 4 [1.3] 4 [1.5] 14 [1.4] Hepatodiaphragmatic Nodule 2 Infarct 1 [4.0] Inflammation 31 [1.3] 25 [1.3] 29 [1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] Mixed Cell Focus 5 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] Tension Lipidosis 2 [1.0] 3 [3.3] 4 [1.8] 2 [1.5] Thrombosis 2 [1.0] 3 [3.3] 4 [1.8] 2 [1.5] Vacuolization Cytoplasmic 10 [2.0] 23 [3.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [2.0] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hyperrophy 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] Vay Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Vagnentation 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0]		(50)	(50)		(50)	
Basophilic Focus 5 7 7 7 Clear Cell Focus 29 31 29 23 Cytoplasmic Alteration 1 [1,0] 1 [2,0] Degeneration, Fatty 1 [3,0] 2 Eosinophilic Focus 31 32 31 26 Fibrosis 1 [2,0] 4 [1,3] 4 [1,5] 14 [1,4] Hematopoietic Cell Proliferation 4 [1,3] 4 [1,5] 14 [1,4] Hematopoietic Cell Proliferation 2 1 [4,0] 14 [1,4] Hematopoietic Cell Proliferation 2 [1,0] 2 [1,0] 2 [1,0] Inflammation 31 [2,0] 5 6 6 Necosis 5 [1,6] 3 [2,0] 1 [3,0] 4 [3,0] Pigmentation 2 [2,0] 3 [1,3] 4 [1,8] 2 [1,5] T				1 [2.0]		
Clear Cell Focus 29 31 29 23 Cytoplasmica Alteration 1 [1.0] 1 [2.0] Degeneration, Fatty 1 [3.0] 1 [2.0] Eosinophilic Focus 31 32 31 26 Fibrosis 1 [2.0] 1 [4.1] 4 [1.5] 14 [1.4] Hematopoietic Cell Proliferation 4 [1.3] 4 [1.5] 14 [1.4] Hepatodiaphragmatic Nodule 2 1 [4.0] 1 [4.0] Inflarct 1 [4.0] 1 [4.0] 1 [4.0] Inflammation 31 [1.3] 25 [1.3] 29 [1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] 1 [3.0] 24 [3.0] Mixed Cell Focus 5 5 6 5 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] 1 [2.0] 2 [1.5] Thrombosis 1 [2.0] 2 [3.1] 1 [9.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Cytoplasmic Alteration 1 [1.0] 1 [2.0] Degeneration, Fatty 1 [3.0] 1 [3.0] Eosinophilic Focus 31 32 31 26 Fibrosis 1 [2.0] 4 [1.3] 4 [1.5] 14 [1.4] Hematopoietic Cell Proliferation 4 [1.3] 4 [1.5] 14 [1.4] Hepatodiaphragmatic Nodule 2 1 [4.0] 1 [4.0] Inflarmation 31 [1.3] 25 [1.3] 29 [1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] 1 [3.0] 24 [1.4] Mixed Cell Focus 5 5 6 5 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] 4 [3.0] 4 [3.0] 4 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0] 9 [3.0	•					
Degeneration, Fatty		29			23	
Eosinophilic Focus 31 32 31 26				1 [2.0]		
Fibrosis 1 [2.0] Hematopoietic Cell Proliferation 4 [1.3] 4 [1.5] 14 [1.4] Hepatodiaphragmatic Nodule 2 Infarct 1 [4.0] Inflammation 31 [1.3] 25 [1.3] 29 [1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] Mixed Cell Focus 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [3.0] 4 [3.0] Pegmentation 1 [3.0] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Kupffer Cell, Hypertrophy 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0]						
Hematopoietic Cell Proliferation	•		32	31	26	
Hepatodiaphragmatic Nodule 2	Fibrosis	1 [2.0]				
Infarct 1 [4.0] Inflammation 31 [1.3] 25 [1.3] 29 [1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] Mixed Cell Focus 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0]	Hematopoietic Cell Proliferation		4 [1.3]	4 [1.5]	14 [1.4]	
Inflammation 31 [1.3] 25 [1.3] 29 [1.3] 24 [1.4] Metaplasia, Osseous 1 [2.0] 1 [2.0] Mixed Cell Focus 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] 1 [2.0] 2 [1.5] Thrombosis 1 [2.0] 2 [1.6] 5 Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] 3 [1.3] 2 [2.0] Hepatocyte, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Hepatodiaphragmatic Nodule	2				
Metaplasia, Osseous 1 [2.0] Mixed Cell Focus 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] 7 [2.0] 2 [1.5] 1 [2.0] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] 1 [2.0] Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] 6 [1.5] Bile Duct, Cyst 3 [3.0] 3 [1.3] 2 [2.0] 2 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0]	Infarct			1 [4.0]		
Mixed Cell Focus 5 5 6 Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0]	Inflammation	31 [1.3]	25 [1.3]	29 [1.3]	24 [1.4]	
Necrosis 5 [1.6] 3 [2.0] 1 [3.0] 4 [3.0] Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] 23 [1.3] 4 [1.8] 2 [1.5] Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Metaplasia, Osseous	1 [2.0]				
Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] 1 [2.0] 2 [1.5] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 3 [1.3] 2 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Mixed Cell Focus	5	5	6		
Pigmentation 2 [2.0] 1 [2.0] 2 [1.5] Regeneration 1 [3.0] 1 [2.0] 2 [1.5] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Necrosis	5 [1.6]	3 [2.0]	1 [3.0]	4 [3.0]	
Regeneration 1 [3.0] Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Pigmentation	2 [2.0]		1 [2.0]	2 [1.5]	
Tension Lipidosis 2 [1.0] 3 [1.3] 4 [1.8] 2 [1.5] Thrombosis 1 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Regeneration					
Thrombosis 1 [2.0] Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Muspertery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]			3 [1.3]	4 [1.8]	2 [1.5]	
Vacuolization Cytoplasmic 10 [2.0] 23 [1.3] 19 [1.6] 6 [1.5] Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]						
Bile Duct, Cyst 3 [3.0] Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]	Vacuolization Cytoplasmic	10 [2.0]		19 [1.6]	6 [1.5]	
Bile Duct, Hyperplasia 2 [2.5] 1 [2.0] 3 [1.3] 2 [2.0] Hepatocyte, Hypertrophy 1 [2.0] 1 [2.0] 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]						
Hepatocyte, Hypertrophy 1 [2.0] Kupffer Cell, Hyperplasia 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]		2 [2.5]	1 [2.0]	3 [1.3]		
Kupffer Cell, Hyperplasia 1 [2.0] 1 [2.0] Kupffer Cell, Pigmentation 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]						
Kupffer Cell, Pigmentation 1 [2.0] Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]					1 [2.0]	
Oval Cell, Hyperplasia 2 [2.5] 1 [2.0] 1 [2.0] Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]					. [=.0]	
Mesentery (8) (6) (8) (10) Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]				1 [2 0]	1 [2 0]	
Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 2 [3.0]			(6)			
Fat Necrosis 4 [3.5] 2 [4.0] 3 [3.0] 3 [3.0]	Fat, Necrosis	4 [3.5]	2 [4.0]	3 [3.0]	3 [3.0]	
Oral Mucosa (0) (0) (0) (1)						

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Pancreas	(50)	(50)	(50)	(50)	
Cytoplasmic Alteration, Focal	1 [1.0]	, ,	, ,	, ,	
Hemorrhage		1 [3.0]			
Infiltration Cellular, Mononuclear Cell	9 [1.0]	14 [1.0]	15 [1.0]	9 [1.0]	
Inflammation	2 [1.0]			1 [1.0]	
Pigmentation				1 [1.0]	
Vacuolization Cytoplasmic	1 [1.0]				
Acinus, Atrophy	2 [2.0]	2 [1.5]	1 [1.0]		
Duct, Cyst	1 [3.0]			1 [2.0]	
Salivary Glands	(50)	(50)	(50)	(50)	
Atrophy	ζ /	1 [2.0]	1 [2.0]	,	
Infiltration Cellular, Mononuclear Cell	40 [1.1]	40 [1.1]	41 [1.1]	40 [1.1]	
Inflammation	[]		[]	2 [1.0]	
Mineralization	1 [1.0]	1 [1.0]	2 [1.5]	_ []	
Duct, Hyperplasia	. []	. []	1 [2.0]		
Submandibular Gland, Vacuolization Cytoplasmic	1 [2.0]		. []		
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Hyperplasia		1 [3.0]			
Inflammation	2 [2.5]	5 [1.4]	3 [2.3]	5 [1.8]	
Ulcer	2 [1.5]			2 [2.0]	
Epithelium, Cyst			1 [3.0]		
Epithelium, Hyperkeratosis	4 [2.0]	3 [2.3]	6 [2.3]	5 [2.2]	
Epithelium, Hyperplasia, Squamous	3 [2.0]	5 [2.2]	6 [2.3]	7 [2.7]	
Stomach, Glandular	(50)	(50)	(50)	(50)	
Cyst	6 [1.0]	19 [1.0]	14 [1.2]	10 [1.2]	
Foreign Body		1			
Hyperplasia	5 [1.4]	5 [2.2]	1 [2.0]	5 [2.0]	
Infiltration Cellular, Mononuclear Cell		4 [1.0]	2 [1.0]		
Inflammation		1 [1.0]	5 [1.6]		
Inflammation, Granulomatous		- ·	1 [2.0]		
Mineralization	1 [1.0]	2 [1.0]			
Tooth	(36)	(30)	(24)	(22)	
Dysplasia	35	27	21	21	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
CARDIOVASCULAR SYSTEM					
Blood Vessel	(50)	(50)	(50)	(50)	
Aorta, Infiltration Cellular, Mononuclear Cell		1 [1.0]			
Aorta, Mineralization		1 [1.0]			
Carotid Artery, Inflammation	1 [1.0]		3 [2.3]		
Carotid Artery, Thrombosis			1 [2.0]		
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	45 [1.9]	44 [1.7]	46 [1.8]	44 [1.9]	
Infiltration Cellular, Mononuclear Cell	1 [1.0]	2 [1.0]	1 [2.0]	4 [1.0]	
Inflammation	2 [1.0]	5 [1.2]	4 [1.3]	2 [1.5]	
Metaplasia, Osseous		1 [3.0]			
Mineralization	1 [1.0]		2 [1.5]	2 [1.5]	
Necrosis	1 [2.0]				
Thrombosis	1 [4.0]				
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Angiectasis		2 [2.0]	2 [1.5]	1 [2.0]	
Fibrosis	1 [1.0]				
Hematopoietic Cell Proliferation				2 [1.5]	
Hyperplasia	1 [1.0]				
Hypertrophy	15 [1.7]	18 [1.4]	13 [1.8]	8 [1.6]	
Inflammation		1 [1.0]			
Mineralization			1 [1.0]		
Vacuolization Cytoplasmic			1 [1.0]		
Subcapsular, Hyperplasia	40 [1.4]	39 [1.3]	44 [1.3]	44 [1.4]	
Adrenal Medulla	(50)	(50)	(50)	(50)	
Hyperplasia			1 [2.0]		
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	43 [2.6]	43 [2.3]	42 [2.3]	40 [2.1]	
Parathyroid Gland	(41)	(44)	(42)	(47)	
Hyperplasia	1 [1.0]				
Pituitary Gland	(50)	(50)	(50)	(50)	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

Opecies/Otrain: MIOL/DOOSI 1			Lab. DAT			
B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG		
Inflammation	1 [3.0]					
Pars Distalis, Hyperplasia	2 [1.0]	1 [1.0]	2 [1.5]	1 [2.0]		
Pars Intermedia, Hyperplasia	_[]	. [•]	1 [3.0]	. [=.0]		
Thyroid Gland	(50)	(50)	(50)	(50)		
Follicular Cell, Hyperplasia	(/	(/	1 [3.0]	(/		
GENERAL BODY SYSTEM						
Peritoneum	(0)	(1)	(1)	(1)		
Hyperplasia			1 [3.0]			
Inflammation		1 [2.0]		1 [3.0]		
GENITAL SYSTEM						
Coagulating Gland	(0)	(2)	(1)	(0)		
Epididymis	(50)	(50)	(50)	(50)		
Fibrosis	1 [4.0]		2 [2.5]			
Granuloma Sperm		2 [2.0]		1 [3.0]		
Infiltration Cellular, Mononuclear Cell	37 [1.0]	38 [1.1]	39 [1.2]	33 [1.1]		
Inflammation	3 [2.0]	4 [1.5]	1 [1.0]	2 [1.5]		
Inflammation, Granulomatous		1 [2.0]				
Mineralization			1 [1.0]			
Pigmentation		1 [1.0]				
Artery, Inflammation		1 [2.0]				
Epithelium, Hyperplasia				1 [2.0]		
Penis	(1)	(0)	(0)	(0)		
Inflammation	1 [2.0]					
Preputial Gland	(50)	(50)	(50)	(50)		
Cyst				1 [4.0]		
Ectasia	3 [3.0]	3 [3.7]	5 [3.6]	2 [3.0]		
Infiltration Cellular, Mononuclear Cell	20 [1.2]	22 [1.4]	22 [1.6]	26 [1.1]		
Inflammation	12 [2.7]	21 [2.3]	14 [1.6]	11 [2.0]		
Prostate	(50)	(50)	(50)	(50)		
Fibrosis		1 [1.0]				
Hyperplasia	12 [1.0]	21 [1.1]	15 [1.1]	19 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Hypertrophy	1 [1.0]				
Infiltration Cellular, Mononuclear Cell	42 [1.0]	44 [1.0]	43 [1.0]	38 [1.0]	
Inflammation	1 [2.0]	4 [2.5]	4 [2.0]	3 [1.7]	
Artery, Inflammation		1 [2.0]			
Seminal Vesicle	(50)	(50)	(50)	(50)	
Infiltration Cellular, Mixed Cell	1 [2.0]	,	,	,	
Infiltration Cellular, Mononuclear Cell	8 [1.4]	12 [1.1]	19 [1.0]	14 [1.0]	
Inflammation		5 [1.8]	1 [1.0]	1 [1.0]	
Bilateral, Dilatation	1 [3.0]	2 [4.0]			
Testes	(50)	(50)	(50)	(50)	
Atrophy	1 [2.0]	, ,	1 [2.0]	, ,	
Infiltration Cellular, Mononuclear Cell	1 [1.0]		2 [1.0]		
Mineralization		1 [1.0]		1 [1.0]	
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Hyperplasia	3 [2.0]	10 [1.4]	8 [2.3]	15 [2.4]	
Lymph Node	(10)	(12)	(9)	(16)	
Axillary, Hyperplasia, Lymphoid			1 [4.0]	3 [3.3]	
Bronchial, Hyperplasia, Lymphoid	1 [1.0]	2 [2.5]	1 [3.0]		
Inguinal, Hyperplasia, Lymphoid	6 [1.7]	6 [2.0]	8 [1.5]	10 [1.4]	
Inguinal, Pigmentation		1 [2.0]			
Mediastinal, Hyperplasia, Lymphoid				3 [3.0]	
Mediastinal, Inflammation				1 [3.0]	
Renal, Necrosis				1 [2.0]	
Lymph Node, Mandibular	(50)	(50)	(50)	(50)	
Hematopoietic Cell Proliferation				1 [3.0]	
Hyperplasia, Lymphoid	9 [1.6]	16 [1.7]	12 [2.0]	11 [1.8]	
Inflammation				1 [2.0]	
Lymph Node, Mesenteric	(50)	(49)	(50)	(49)	
Angiectasis			1 [3.0]		
Hyperplasia, Lymphoid	5 [2.2]	7 [1.7]	10 [2.2]	3 [3.0]	
Inflammation	1 [2.0]		1 [2.0]	1 [3.0]	
Pigmentation	1 [2.0]				

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Spleen	(50)	(49)	(50)	(50)	
Angiectasis	,	,	,	1 [1.0]	
Hematopoietic Cell Proliferation	37 [1.6]	38 [1.4]	40 [1.7]	42 [2.1]	
Hyperplasia, Lymphoid	5 [2.2]	2 [1.5]	3 [2.3]	5 [2.2]	
Inflammation				1 [2.0]	
Pigmentation			1 [1.0]		
Thymus	(48)	(50)	(46)	(48)	
Hyperplasia, Lymphoid	2 [2.0]	2 [2.5]	1 [3.0]	1 [2.0]	
INTEGUMENTARY SYSTEM					
Mammary Gland	(0)	(0)	(0)	(1)	
Hyperplasia				1 [1.0]	
Skin	(50)	(50)	(50)	(50)	
Abscess		1			
Fibrosis	1 [2.0]	1 [4.0]	3 [4.0]	10 [3.6]	
Hyperkeratosis	1 [2.0]	1 [2.0]	3 [2.7]	10 [3.1]	
Hyperplasia	1 [2.0]	1 [3.0]	3 [3.7]	10 [3.3]	
Inflammation	1 [4.0]	1 [4.0]	3 [4.0]	10 [3.5]	
Metaplasia, Cartilagenous				1 [1.0]	
Ulcer		1 [2.0]	3 [4.0]	10 [3.7]	
Control, Inflammation			1 [1.0]	1 [3.0]	
Hair Follicle, Site Of Application, Cyst				1	
Lip, Inflammation		1 [1.0]			
Sebaceous Gland, Hyperplasia	1 [1.0]	1 [1.0]		5 [1.8]	
Sebaceous Gland, Site Of Application, Hyperplasia	1 [2.0]	6 [1.3]	4 [1.3]	24 [1.5]	
Site Of Application, Fibrosis	3 [2.0]	6 [1.7]	28 [1.4]	47 [2.5]	
Site Of Application, Hyperkeratosis	11 [1.5]	43 [1.3]	50 [1.9]	50 [2.6]	
Site Of Application, Hyperplasia	8 [1.3]	24 [1.2]	47 [1.6]	50 [2.5]	
Site Of Application, Inflammation	2 [1.5]	6 [1.7]	37 [1.2]	44 [2.4]	
Site Of Application, Pigmentation			9 [1.0]	39 [1.5]	
Site Of Application, Ulcer	1 [2.0]	1 [3.0]	2 [2.5]	23 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
MUSCULOSKELETAL SYSTEM					
WOOCOLOGICLE TAL STOTEW					
Bone	(50)	(50)	(50)	(50)	
Cranium, Hyperostosis			1 [3.0]	1 [2.0]	
Cranium, Inflammation	1 [3.0]			1 [2.0]	
Skeletal Muscle	(0)	(0)	(1)	(2)	
Inflammation			1 [1.0]		
Mineralization				1 [1.0]	
NERVOUS SYSTEM					
Brain	(50)	(50)	(50)	(50)	
Developmental Malformation	1 [1.0]				
Infiltration Cellular, Mononuclear Cell	4 [1.0]	2 [1.0]		1 [1.0]	
Inflammation	1 [1.0]			1 [1.0]	
Cerebellum, Gliosis				1 [1.0]	
Choroid Plexus, Mineralization	1 [1.0]				
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Infiltration Cellular, Histiocyte	5 [2.4]	12 [1.8]	7 [2.7]	6 [2.3]	
Inflammation	7 [1.9]	3 [1.7]	5 [1.8]	3 [1.7]	
Metaplasia, Osseous		1 [1.0]		2 [1.0]	
Mineralization		1 [1.0]	1 [1.0]		
Pigmentation	1 [1.0]	3 [1.0]	2 [1.0]		
Thrombosis	F -3	1	1 [3.0]		
Alveolar Epithelium, Hyperplasia	7 [1.9]	3 [1.3]	3 [1.7]	5 [1.2]	
Bronchiole, Hyperplasia	r - 1	1 [1.0]	- 1 1	1 [2.0]	
Bronchiole, Mineralization	1 [1.0]	r -1		r -a	
Interstitium, Fibrosis	[]		1 [2.0]		
Mediastinum, Necrosis, Fatty			. []	1 [2.0]	
Nose	(50)	(50)	(50)	(50)	
Foreign Body	(/	(/	1	(/	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Inflammation	20 [1.2]	15 [1.4]	16 [1.1]	15 [1.2]	
Necrosis				1 [3.0]	
Polyp, Inflammatory	2 [2.5]	2 [2.0]	2 [3.0]	1 [3.0]	
Glands, Dilatation	2 [1.0]		1 [1.0]	2 [1.0]	
Glands, Fibrosis	1 [2.0]				
Glands, Metaplasia	11 [1.5]	3 [1.0]	1 [1.0]	3 [1.0]	
Goblet Cell, Hyperplasia				2 [1.5]	
Olfactory Epithelium, Degeneration	2 [1.0]			3 [1.0]	
Olfactory Epithelium, Hyperplasia	1 [1.0]	1 [3.0]	1 [3.0]		
Olfactory Epithelium, Metaplasia	11 [1.5]	8 [1.6]	4 [1.8]	5 [1.6]	
Respiratory Epithelium, Degeneration	2 [1.5]		1 [2.0]		
Respiratory Epithelium, Hyperplasia	40 [1.5]	45 [1.4]	46 [1.4]	37 [1.5]	
Respiratory Epithelium, Metaplasia	2 [2.5]	1 [1.0]		1 [1.0]	
Vomeronasal Organ, Cyst			1 [2.0]		
SPECIAL SENSES SYSTEM					
Eye	(50)	(50)	(50)	(50)	
Cataract			1 [2.0]	1 [3.0]	
Developmental Malformation			1 [4.0]		
Infiltration Cellular, Mononuclear Cell			1 [1.0]		
Inflammation	4 [2.3]	2 [1.5]	3 [1.7]	1 [3.0]	
Cornea, Hyperplasia	2 [1.5]	1 [2.0]		1 [3.0]	
Harderian Gland	(50)	(50)	(50)	(50)	
Cyst	1 [2.0]	()	()	(/	
Hyperplasia	3 [1.3]	1 [1.0]	1 [4.0]	3 [2.7]	
Infiltration Cellular, Mononuclear Cell	35 [1.0]	41 [1.0]	41 [1.0]	36 [1.0]	
Inflammation	1 [2.0]	[0]	[0]	1 [1.0]	
	. [=.4]				
URINARY SYSTEM					
Kidney	(50)	(50)	(50)	(50)	
Accumulation, Hyaline Droplet	• •			1 [2.0]	
Cyst		5	9	4	
Dilatation		2 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Hyperplasia, Oncocytic				1 [3.0]	
Infarct		1 [2.0]			
Infiltration Cellular, Mononuclear Cell	2 [2.0]		5 [1.2]	4 [1.3]	
Inflammation	1 [2.0]	3 [3.0]	2 [2.0]	2 [3.0]	
Metaplasia, Osseous	6 [1.8]	2 [1.5]			
Mineralization	39 [1.2]	42 [1.2]	34 [1.3]	38 [1.1]	
Nephropathy	44 [1.6]	46 [1.4]	47 [1.8]	45 [1.6]	
Pigmentation	1 [2.0]			1 [2.0]	
Thrombosis	1 [2.0]	1 [1.0]			
Papilla, Necrosis		1 [3.0]			
Renal Tubule, Hyperplasia	3 [1.0]	2 [2.0]	1 [1.0]	1 [1.0]	
Urethra	(0)	(1)	(1)	(1)	
Inflammation		1 [2.0]		1 [3.0]	
Bulbourethral Gland, Inflammation		1 [3.0]	1 [3.0]		
Bulbourethral Gland, Necrosis		1 [4.0]			
Transitional Epithelium, Hyperplasia		1 [2.0]			
Urinary Bladder	(50)	(50)	(50)	(50)	
Infiltration Cellular, Mononuclear Cell	20 [1.0]	31 [1.0]	33 [1.1]	23 [1.0]	
Inflammation		1 [1.0]	2 [2.0]		

^{***} END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

-p					
B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Disposition Summary					
Animals Initially In Study	50	50	50	50	
Early Deaths	U U	oo -	•	00	
Moribund Sacrifice	9	15	7	29	
Natural Death	8	5	7	4	
Survivors					
Natural Death				1	
Terminal Sacrifice	33	30	36	16	
Animals Examined Microscopically	50	50	50	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Inflammation	()	,	1 [1.0]	,	
Epithelium, Hyperplasia			1 [2.0]		
Gallbladder	(50)	(49)	(49)	(50)	
Cyst	1 [1.0]	, ,	, ,	1 [2.0]	
Infiltration Cellular, Mononuclear Cell	4 [1.0]	7 [1.0]	6 [1.0]	6 [1.0]	
Inflammation	1 [1.0]				
Epithelium, Hyperplasia		1 [2.0]			
Intestine Large, Cecum	(50)	(50)	(50)	(50)	
Inflammation	1 [1.0]				
Epithelium, Hyperplasia		1 [2.0]			
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Artery, Inflammation				1 [2.0]	
Intestine Large, Rectum	(50)	(50)	(50)	(50)	
Artery, Inflammation				1 [3.0]	
Epithelium, Hyperplasia			1 [1.0]		
Intestine Small, Duodenum	(50)	(50)	(50)	(50)	
Inflammation	1 [2.0]				
Epithelium, Hyperplasia			1 [2.0]		
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Inflammation	1 [2.0]	1 [2.0]		1 [3.0]	
Epithelium, Hyperplasia	1 [3.0]	1 [3.0]	3 [1.7]		
Intestine Small, Jejunum	(50)	(50)	(50)	(50)	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol CAS Number: 87-66-1

Time Report Requested: 13:34:47

First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
	0.14.53	- I I O	0.10.01	0.14.03	
Hyperplasia, Lymphoid	2 [1.5]	5 [1.2]	2 [2.0]	2 [1.0]	
Inflammation			2 [1.5]		
Epithelium, Hyperplasia	(= - \)	4	1 [1.0]	/ ->	
Liver	(50)	(50)	(50)	(50)	
Angiectasis	2 [2.5]		2 [2.5]		
Atrophy			1 [3.0]		
Basophilic Focus	8	2	3	2	
Clear Cell Focus	10	1	3	1	
Eosinophilic Focus	26	28	31	12	
Fibrosis	1 [2.0]	1 [2.0]			
Hematopoietic Cell Proliferation	9 [1.4]	8 [1.9]	9 [1.4]	30 [1.3]	
Hypertrophy, Diffuse			1 [3.0]		
Inflammation	40 [1.5]	32 [1.4]	43 [1.5]	37 [1.5]	
Mixed Cell Focus	6	7	4	1	
Necrosis	8 [2.3]	5 [2.0]	2 [2.5]	6 [1.8]	
Pigmentation		1 [2.0]			
Tension Lipidosis	7 [1.6]	6 [1.3]	7 [1.1]	10 [1.0]	
Vacuolization Cytoplasmic	7 [1.4]	5 [1.4]	6 [1.2]	1 [1.0]	
Centrilobular, Hepatocyte, Degeneration	1 [3.0]				
Mesentery	(20)	(22)	(14)	(19)	
Inflammation	2 [2.5]	2 [2.5]	, ,	1 [1.0]	
Thrombosis	1 [1.0]				
Fat, Necrosis	12 [3.8]	10 [3.4]	11 [3.8]	15 [3.7]	
Fat, Thrombosis		1 [4.0]			
Pancreas	(50)	(50)	(50)	(50)	
Atrophy	(7	()	()	1 [2.0]	
Infiltration Cellular, Mononuclear Cell	31 [1.1]	25 [1.1]	24 [1.1]	21 [1.0]	
Inflammation	3 [1.0]		[]	4 [1.5]	
Acinus, Atrophy	3 [2.3]	1 [1.0]	1 [1.0]	2 [1.5]	
Artery, Inflammation	0 [=.0]	1 [2.0]	. [•]	_ [0]	
Duct, Cyst	1 [3.0]	. [=.0]			
Salivary Glands	(50)	(50)	(50)	(50)	
Atrophy	(50)	(30)	(30)	1 [2.0]	
Infiltration Cellular, Mononuclear Cell	36 [1.2]	37 [1.3]	38 [1.2]	30 [1.2]	
Inflammation	00 [1.2]	or [1.0]	1 [2.0]	1 [1.0]	
Mineralization		1 [1.0]	ا رکان	2 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Hyperplasia	, ,	1 [4.0]	, ,	, ,	
Infiltration Cellular, Mononuclear Cell			1 [1.0]	2 [1.0]	
Infiltration Cellular, Diffuse				1 [4.0]	
Inflammation		5 [1.8]	2 [2.5]		
Ulcer		3 [2.0]	1 [3.0]		
Epithelium, Hyperkeratosis	1 [2.0]	6 [2.7]	2 [3.5]	1 [2.0]	
Epithelium, Hyperplasia, Squamous	2 [1.5]	9 [2.7]	3 [3.0]	1 [2.0]	
Stomach, Glandular	(50)	(50)	(50)	(50)	
Cyst	15 [1.1]	18 [1.1]	15 [1.0]	14 [1.0]	
Hyperplasia	3 [2.0]	1 [2.0]	1 [1.0]	4 [1.8]	
Infiltration Cellular, Mononuclear Cell	1 [1.0]	4 [1.3]	5 [1.0]	2 [1.0]	
Infiltration Cellular, Diffuse				1 [3.0]	
Inflammation		3 [1.3]	1 [3.0]	1 [1.0]	
Mineralization			1 [1.0]	2 [1.0]	
Necrosis		1 [2.0]			
Ulcer		1 [2.0]	1 [3.0]		
Tooth	(3)	(0)	(4)	(0)	
Dysplasia	3	()	4	()	
CARDIOVASCULAR SYSTEM					
Blood Vessel	(50)	(50)	(50)	(50)	
Inflammation	1 [2.0]				
Carotid Artery, Mineralization		1 [2.0]			
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	42 [1.3]	33 [1.4]	35 [1.1]	38 [1.4]	
Infiltration Cellular, Mononuclear Cell	1 [1.0]	3 [1.0]	4 [1.0]	3 [1.0]	
Inflammation	3 [2.0]	3 [1.7]	1 [2.0]	2 [1.0]	
Mineralization	2 [1.5]	4 [2.5]	2 [2.0]		
Thrombosis	3 [2.3]	1 [2.0]	1 [1.0]		
Myocardium, Vacuolization Cytoplasmic			1 [2.0]		

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Adrenal Cortex	(50)	(50)	(50)	(50)	
Angiectasis	, ,		2 [2.0]	1 [1.0]	
Degeneration, Cystic				1 [2.0]	
Hematopoietic Cell Proliferation	3 [1.3]	4 [1.8]	4 [1.0]	14 [1.4]	
Hyperplasia			1 [1.0]		
Hypertrophy	4 [1.3]	2 [2.5]	5 [1.8]	2 [1.0]	
Subcapsular, Hyperplasia	50 [1.7]	49 [1.6]	49 [1.7]	49 [1.8]	
Adrenal Medulla	(50)	(50)	(50)	(50)	
Hyperplasia	1 [1.0]	3 [1.7]	2 [1.5]	2 [2.0]	
Hypertrophy	• •	1 [1.0]			
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	35 [1.2]	15 [1.5]	12 [1.5]	8 [1.3]	
Parathyroid Gland	(45)	(47)	(39)	(38)	
Cyst	, ,		2 [1.0]	1 [3.0]	
Hyperplasia			2 [2.0]		
Pituitary Gland	(50)	(49)	(50)	(50)	
Angiectasis	1 [3.0]	1 [2.0]	,	, ,	
Hemorrhage	1 [3.0]		1 [3.0]	1 [3.0]	
Pars Distalis, Degeneration	• •			1 [1.0]	
Pars Distalis, Hyperplasia	17 [1.7]	18 [1.6]	19 [1.8]	17 [1.7]	
Thyroid Gland	(50)	(50)	(50)	(50)	
Infiltration Cellular, Mononuclear Cell	1 [1.0]	,	2 [1.5]	2 [1.0]	
Follicular Cell, Hyperplasia		1 [1.0]			
GENERAL BODY SYSTEM					
Peritoneum	(1)	(0)	(0)	(0)	
Inflammation	1 [2.0]				
Tissue NOS	(1)	(0)	(0)	(0)	
GENITAL SYSTEM					
Clitoral Gland	(49)	(50)	(50)	(49)	
Infiltration Cellular, Mononuclear Cell	(/	2 [1.0]	2 [1.0]	1 [1.0]	
Inflammation	10 [1.4]	10 [1.1]	8 [1.0]	9 [1.2]	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Ovary	(50)	(50)	(50)	(50)	
Angiectasis	()	1 [2.0]	2 [2.5]	(23)	
Cyst	7 [2.1]	15 [2.0]	13 [1.9]	14 [1.6]	
Infiltration Cellular, Mononuclear Cell		5 [2.2]	6 [2.2]	1	
Inflammation	2 [2.5]		2 [1.5]	1 [1.0]	
Mineralization	1 [3.0]			1 [1.0]	
Necrosis	1 [4.0]			,	
Pigmentation	1 [1.0]				
Thrombosis	1	1 [2.0]			
Germinal Epithelium, Hyperplasia		1 [2.0]	1 [1.0]	1 [2.0]	
Oviduct	(1)	(0)	(0)	(0)	
Infiltration Cellular, Mononuclear Cell	1 [2.0]	()	()	,	
Uterus	(50)	(50)	(50)	(50)	
Angiectasis	1 [3.0]	,	1 [2.0]	,	
Inflammation	7 [1.7]	6 [1.8]	8 [2.5]	4 [1.5]	
Pigmentation		1 [2.0]			
Thrombosis	3 [3.7]		1 [3.0]	1 [4.0]	
Ulcer		2 [3.0]	1 [2.0]		
Cervix, Hyperplasia, Cystic				1 [4.0]	
Endometrium, Hyperplasia, Cystic	46 [2.8]	46 [2.8]	46 [3.0]	43 [2.6]	
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Hyperplasia	10 [1.9]	14 [2.0]	10 [1.7]	31 [2.7]	
Lymph Node	(19)	(13)	(18)	(29)	
Axillary, Hyperplasia, Lymphoid				8 [3.8]	
Axillary, Inflammation				1 [2.0]	
Axillary, Pigmentation				1 [2.0]	
Bronchial, Hyperplasia, Lymphoid	4 [1.5]	1 [3.0]	5 [2.0]	5 [2.0]	
Inguinal, Hyperplasia, Lymphoid	4 [1.5]	2 [2.0]	7 [1.9]	17 [2.4]	
Inguinal, Inflammation, Granulomatous	1 [4.0]				
Lumbar, Angiectasis			1 [4.0]		
Lumbar, Hyperplasia, Lymphoid	2 [2.5]		1 [4.0]		
Lumbar, Inflammation	1 [3.0]				

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Mediastinal, Hyperplasia, Lymphoid		2 [3.0]	1 [2.0]		
Mediastinal, Infiltration Cellular, Histiocyte	1 [3.0]	2 [0.0]	. [2.0]		
Pancreatic, Hyperplasia, Lymphoid	. [0.0]		2 [2.0]		
Renal, Angiectasis			1 [4.0]		
Renal, Hyperplasia, Lymphoid	1 [4.0]		. [•]	1 [2.0]	
Lymph Node, Mandibular	(50)	(50)	(50)	(50)	
Hyperplasia, Lymphoid	14 [1.8]	19 [1.7]	23 [1.6]	27 [2.1]	
Inflammation	[0]		_0 [0]	1 [2.0]	
Pigmentation				1 [1.0]	
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)	
Atrophy	(00)	(00)	2 [2.5]	(33)	
Hematopoietic Cell Proliferation			2 [2.0]	1 [2.0]	
Hyperplasia, Lymphoid	13 [1.9]	12 [2.1]	13 [1.7]	4 [1.8]	
Inflammation	2 [2.0]	1 [2.0]	.0[]	1 [2.0]	
Artery, Inflammation	2 [2.0]	. [2.0]		1 [2.0]	
Spleen	(50)	(50)	(50)	(50)	
Atrophy	(00)	(00)	1 [3.0]	(33)	
Hematopoietic Cell Proliferation	35 [2.1]	35 [2.2]	30 [1.8]	34 [2.5]	
Hyperplasia, Lymphoid	8 [2.3]	5 [2.2]	11 [2.0]	7 [2.7]	
Inflammation	1 [2.0]	○ [=·=j	[=.0]	. [=]	
Pigmentation	12 [1.3]	8 [1.1]	18 [1.1]	7 [1.0]	
Thymus	(50)	(50)	(48)	(49)	
Angiectasis	(00)	1 [3.0]	(10)	(13)	
Atrophy		1 [3.0]	1 [2.0]		
Hemorrhage	1 [2.0]	. [0.0]	. [2.0]		
Hyperplasia, Lymphoid	18 [2.2]	21 [1.8]	25 [2.1]	22 [2.0]	
Inflammation	. 0 [2.2]	2. [0]	1 [2.0]	(- 0)	
INTEGUMENTARY SYSTEM					
Mammary Gland	(50)	(50)	(50)	(50)	
Hyperplasia	5 [1.4]	9 [1.4]	3 [2.0]	16 [1.6]	
Inflammation		2 [1.5]		1 [1.0]	
Duct, Dilatation		1 [1.0]		2 [2.0]	
Skin	(50)	(50)	(50)	(50)	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Abscess		1			
Fibrosis	1 [3.0]	2 [3.5]	1 [4.0]	9 [4.0]	
Hyperkeratosis	1 [4.0]	2 [3.0]	1 [4.0]	9 [3.3]	
Hyperplasia	1 [4.0]	2 [3.0]	1 [4.0]	9 [3.9]	
Inflammation	1 [3.0]	-[]	. []	9 [3.7]	
Inflammation, Granulomatous	£1	1 [4.0]		1	
Pigmentation			1 [2.0]	1 [1.0]	
Ulcer	1 [3.0]	1 [2.0]	1 [4.0]	9 [3.4]	
Control, Hyperplasia	£1		,	2 [1.5]	
Control, Inflammation	3 [1.0]		1 [2.0]	2 [1.0]	
Sebaceous Gland, Hyperplasia	1 [2.0]		1 [1.0]	7 [1.3]	
Sebaceous Gland, Site Of Application, Hyperplasia	1 [1.0]	2 [1.0]	6 [1.2]	34 [1.5]	
Site Of Application, Cyst				1	
Site Of Application, Fibrosis	5 [1.8]	6 [1.3]	31 [1.3]	49 [3.1]	
Site Of Application, Hyperkeratosis	24 [1.5]	38 [1.4]	49 [2.7]	49 [3.4]	
Site Of Application, Hyperplasia	20 [1.4]	31 [1.3]	49 [1.9]	49 [3.3]	
Site Of Application, Infiltration Cellular, Mast Cell			1 [2.0]	1 [2.0]	
Site Of Application, Inflammation	12 [1.3]	14 [1.1]	42 [1.2]	48 [3.0]	
Site Of Application, Pigmentation			35 [1.0]	40 [1.8]	
Site Of Application, Ulcer	2 [3.0]		3 [1.3]	33 [3.1]	
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
Fibro-Osseous Lesion	8 [1.9]	9 [1.9]	9 [1.6]	2 [1.5]	
Skeletal Muscle	(4)	(1)	(2)	(0)	
Inflammation	1 [2.0]	(-)	1 [1.0]	(5)	
NERVOUS SYSTEM					
Proin	(FO)	(50)	(FO)	(50)	
Brain Developmental Malformation	(50)	(50)	(50)	(50)	
Developmental Malformation Infiltration Cellular, Mononuclear Cell	4 [4 0]	4 [4 0]	1 [1.0]		
minuation Celiular, Mononuclear Cell	1 [1.0]	1 [1.0]			

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Inflammation	1 [2.0]			1 [1.0]	
Cerebrum, Vacuolization Cytoplasmic	1		1 [2.0]	1	
Peripheral Nerve	(2)	(0)	(0)	(0)	
Sciatic, Atrophy	1 [3.0]	(-)	(-)	(-)	
Sciatic, Infiltration Cellular, Mononuclear Cell	1 [1.0]				
Spinal Cord	(2)	(0)	(0)	(0)	
Atrophy	1 [3.0]	(-)	(-)	(-)	
Degeneration	1 [3.0]				
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Fibrosis				1 [1.0]	
Infiltration Cellular, Histiocyte	2 [2.0]	6 [2.5]	2 [1.0]	2 [3.0]	
Inflammation	3 [1.7]	5 [1.6]	1 [1.0]	2 [1.5]	
Metaplasia, Osseous	2 [1.0]				
Pigmentation	1 [1.0]		1 [2.0]		
Thrombosis	1 [3.0]				
Artery, Mineralization	1 [1.0]				
Bronchiole, Hyperplasia		1 [3.0]		1 [3.0]	
Nose	(50)	(50)	(50)	(50)	
Inflammation	13 [1.1]	9 [1.2]	17 [1.1]	9 [1.0]	
Polyp, Inflammatory			1 [3.0]		
Glands, Dilatation	2 [1.0]				
Glands, Metaplasia	6 [1.0]	7 [1.0]	3 [1.0]	7 [1.0]	
Olfactory Epithelium, Hyperplasia	-	-	1 [2.0]		
Olfactory Epithelium, Metaplasia		3 [1.7]	2 [1.0]	2 [1.5]	
Respiratory Epithelium, Foreign Body			1 [1.0]		
Respiratory Epithelium, Hemorrhage	1 [1.0]		1 [2.0]		
Respiratory Epithelium, Hyperplasia	46 [1.5]	48 [1.5]	46 [1.6]	46 [1.4]	
Turbinate, Thrombosis	1 [3.0]				
Trachea	(50)	(50)	(50)	(50)	
Inflammation	` '	, ,	1 [2.0]	, ,	
Epithelium, Hyperplasia			1 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number:** 87-66-1

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
SPECIAL SENSES SYSTEM					
	()	()	()	(==)	
Eye	(50)	(50)	(50)	(50)	
Atrophy			1 [3.0]		
Infiltration Cellular, Mononuclear Cell	1 [1.0]	1 [1.0]		1 [1.0]	
Inflammation	2 [1.5]		1 [1.0]	3 [2.0]	
Cornea, Hyperplasia	1 [3.0]				
Retina, Angiectasis			1 [1.0]		
Retina, Degeneration		1 [3.0]			
Harderian Gland	(50)	(50)	(50)	(50)	
Atrophy			1 [1.0]		
Cyst	1 [1.0]				
Hyperplasia	3 [2.0]	9 [1.3]	6 [1.3]	5 [1.8]	
Infiltration Cellular, Mononuclear Cell	29 [1.0]	33 [1.0]	31 [1.0]	24 [1.0]	
Inflammation	1 [1.0]				
Mineralization				1 [1.0]	
Lacrimal Gland	(0)	(0)	(1)	(0)	
URINARY SYSTEM					
Kidney	(50)	(50)	(50)	(50)	
Accumulation, Hyaline Droplet	2 [2.5]	3 [1.7]	2 [3.0]	(55)	
Cyst	2 [2.0]	0[]	1		
Dilatation		1 [3.0]	'	2 [2.5]	
Infarct, Chronic		1 [0.0]	1 [2.0]	2 [2.0]	
Infiltration Cellular, Mononuclear Cell	2 [1.5]	5 [1.4]	4 [1.5]	4 [1.3]	
Inflammation	1 [3.0]	O [1.1]	1[1.0]	3 [1.7]	
Metaplasia, Osseous	3 [1.0]	1 [1.0]	1 [2.0]	2 [2.0]	
Mineralization	12 [1.3]	7 [1.3]	8 [1.0]	7 [1.0]	
Nephropathy	33 [1.2]	7 [1.3] 24 [1.3]	28 [1.2]	7 [1.0] 28 [1.2]	
Pigmentation	35 [1.2] 3 [2.0]	24 [1.3] 1 [3.0]	26 [1.2] 1 [1.0]	20 [1.2]	
Papilla, Necrosis	3 [2.0]	၊ [၁.0]	1 [1.0]	1 [1 0]	
	1 [2 0]	1 [2 0]	1 [1 0]	1 [1.0]	
Renal Tubule, Degeneration	1 [3.0]	1 [3.0]	1 [1.0]		
Renal Tubule, Hyperplasia	1 [1.0]		4 [0 0]		
Renal Tubule, Vacuolization Cytoplasmic			1 [3.0]		

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/17/2010 AVERAGE SEVERITY GRADES[b]

Pyrogallol **CAS Number: 87-66-1**

Time Report Requested: 13:34:47 First Dose M/F: 09/21/04 / 09/20/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG	
Urinary Bladder	(50)	(50)	(50)	(50)	
Infiltration Cellular, Mononuclear Cell	34 [1.3]	37 [1.2]	37 [1.1]	42 [1.1]	
Inflammation	1 [1.0]	1 [2.0]	1 [1.0]	1 [3.0]	

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)